Certain reflux and ulcer medications linked with bone fractures in dialysis patients

September 27, 2018, American Society of Nephrology

Certain medications commonly used to treat heartburn, acid reflux, and ulcers are linked with higher bone fracture risks among patients on dialysis, according to a new study. Almost three-quarters of patients who had a hip fracture had used the medications in the 3 years preceding their event. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

Among patients who have end-stage kidney disease, or kidney failure, and are on hemodialysis, risk is estimated to be 4 times higher than in the general population. Many patients with kidney failure take medications called (PPIs), which reduce stomach acid production and have been linked with hip fractures in the general population. Theoretically, histamine-2 receptor antagonists, which also reduce gastric acid production, would yield a similar association with hip fracture events if the mechanism of proposed risk involved acid suppression alone. Yet, studies in the conflict on whether these drugs are also linked with fractures.

To examine potential associations in patients with , a team led by Chandan Vangala, MD and Wolfgang Winkelmayer, MD, Ph.D., ScD (Baylor College of Medicine) analyzed information from the US Renal Data System (USRDS) to identify all hip fracture events recorded between 2009 and 2014 among hemodialysis-dependent patients. All cases were matched with 10 patients on dialysis who did not experience hip . Prescription drug information for the preceding 3 years was gathered from Medicare Part D claims.

In the analysis of 4551 hip fracture cases and 45,510 controls, a larger proportion of cases had any prior use of PPIs (70% vs. 63%) or histamine-2 receptor antagonists (25% vs. 23%). After adjustments, use of PPIs was associated with a 19% higher risk of hip fracture. The association remained within subgroups of low, moderate, and high PPI use, yielding of 16%, 21%, and 19% greater risks, respectively. Histamine-2 receptor antagonists were not associated with hip fracture events.

"Proton pump inhibitors are the sixth most common type of medication prescribed among patients who are dependent on dialysis; however, their use is associated with increased hip fracture risk. Therefore, we recommend interval assessment of continued PPI use in hemodialysis-dependent patients, who already experience tremendous medication burden," said Dr. Vangala.

In an accompanying editorial, Benjamin Lazarus, MBBS and Morgan Grams, MD, Ph.D. (Johns Hopkins Bloomberg School of Public Health) noted that the association between PPI use and hip fracture is biologically plausible, but the observational study cannot definitively assert that PPI use causes hip fracture. "However, a randomized controlled trial to address risks of PPI use in patients receiving hemodialysis is probably not practicable," they wrote. "Based on the available data, we suggest that PPI use in hemodialysis patients be individualized, with discontinuation as soon as medically indicated, and that are counseled about possible adverse effects, including the possibility of heightened risk of hip fracture."

Study co-authors include Jingbo Niu, MD, DSc, Colin Lenihan, MB BCh BAO, Ph.D., William Mitch, MD, and Sankar Navaneethan, MD, MS, MPH.

Disclosures: Dr. Winkelmayer reports having served as an advisor or consultant, unrelated to the topic of this manuscript, to Akebia, Amgen, Astra-Zeneca, Bayer, Daichii-Sankyo, Relypsa, Vifor-Fresenius Medical Care Renal Pharma, and ZS Pharma. Dr. Navaneethan serves on the independent event adjudication committee for clinical trials sponsored by Bayer and Boehringer Ingelheim (unrelated to the topic of this manuscript). All other authors have no financial disclosures to report.

Explore further: Empagliflozin doesn't up risk of bone fractures

More information: Chandan Vangala et al, Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis, Clinical Journal of the American Society of Nephrology (2018). DOI: 10.2215/CJN.02190218

Related Stories

Empagliflozin doesn't up risk of bone fractures

July 23, 2018
(HealthDay)—Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes, according to a study published online June 15 in Diabetes Care.

Opioids may carry unique risks for patients on hemodialysis

April 19, 2018
A new analysis indicates that opioid pain medications may not be as safe for hemodialysis patients as recommendations suggest, and therefore, their use should be limited when possible. The analysis appears in an upcoming ...

Drug may help prevent bone fractures in patients on dialysis

December 11, 2014
A drug that mimics calcium and lowers parathyroid levels may help prevent bone fractures in patients with kidney failure who are on dialysis, according to a study appearing in an upcoming issue of the Journal of the American ...

Short-term PPIs tied to higher hip fracture risk in Alzheimer's

March 22, 2018
(HealthDay)—Short-term proton pump inhibitor use, but not long-term or cumulative use, is associated with an increased risk of hip fracture among Alzheimer's patients, according to a study published online March 6 in Alimentary ...

Long-term proton pump inhibitor use does not increase hip fracture risk among Alzheimer's patients

March 13, 2018
Long-term proton pump inhibitor (PPI) use does not increase the risk of hip fracture among persons with Alzheimer's disease, according to a new study from the University of Eastern Finland. The risk of hip fracture was slightly ...

Increased risk of MI, stroke for patients with hip fracture

August 24, 2017
(HealthDay)—Patients with hip fracture have an increased risk of myocardial infarction (MI) and stroke, according to a study published online Aug. 21 in the Journal of Bone and Mineral Research.

Recommended for you

Scientists shed new light on infection process of the gastrointestinal pathogen C. difficile

November 21, 2018
Scientists from the VIB-UGent Center for Inflammation Research identified the mechanisms by which the bacterial pathogen Clostridium difficile kills intestinal epithelial cells (IECs), thus destroying the protective mucosal ...

As antibiotic resistance grows, researchers find new targets for fighting deadly staph infections

November 21, 2018
A new look at the inner-workings of bacterial cells could help researchers overcome deadly antibiotic resistance and save the lives of tens-of-thousands of people every year.

Can liver disease be linked to heart failure? Study highlights liver-heart interaction

November 21, 2018
Virginia Commonwealth University researchers have collaborated on a clinical trial that identifies indicators for nonalcoholic fatty liver disease—a typically asymptomatic disease caused by fat buildup in the liver and ...

Researchers find infectious prions throughout eyes of patients with deadly sporadic Creutzfeldt-Jakob disease

November 20, 2018
By the time symptoms of sporadic Creutzfeldt-Jakob disease (sCJD) are typically discovered, death is looming and inevitable. But, in a new study, researchers at University of California San Diego School of Medicine with colleagues ...

Researchers a step closer to understanding how deadly bird flu virus takes hold in humans

November 19, 2018
New research has taken a step towards understanding how highly pathogenic influenza viruses such as deadly bird flu infect humans.

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.